Filters
Close
ADDED DATE
Added date
TOPICS Please select
WATCH / LISTEN / READ TIME
Author(s): Added: 2 months ago
AHA Scientific Sessions 2025 - Dr Sarah Cuddy (Brigham and Women's Hospital, US) joins us to discuss the role of non-disease modifying treatments including SGLT2 inhibitors, mineralocorticoid receptor antagonists, GLP-1 receptor agonists, and implantable hemodynamic monitors in cardiac amyloidosis, and what this means for managing heart failure in this unique patient population.Interview… View more
Author(s): Brian Lindman Added: 9 months ago
ACC 2025 - Primary findings from EARLY-TAVR show the benefit of early TAVR intervention was consistent across biomarker subgroups.Dr Brian Lindman (Vanderbilt University Medical Center, Nashville, US) joins us onsite at ACC 2025 to discuss findings from the primary biomarker analysis from the EARLY TAVR trial (NCT03042104; Edwards Lifesciences). The analysis investigated cardiac biomarkers in… View more
Author(s): Harriette Van Spall , Udo Bavendiek Added: 4 months ago
ESC Congress 2025 - Digitoxin reduced the risk of all-cause mortality and hospitalisation in patients with worsening heart failure.Dr Harriette Van Spall (McMaster University, CA) sits down with Prof Udo Bavendiek to explore the DIGIT-HF trial, investigating whether digitoxin can improve outcomes in patients with advanced chronic heart failure and reduced ejection fraction.This landmark study… View more
Author(s): Nobuyuki Kagiyama Added: 2 months ago
AHA Scientific Sessions 2025 - Prof Nobuyuki Kagiyama (Juntendo University School of Medicine, Tokyo, JP) joins us to share findings from the AI-SCREEN-CA study investigating whether an artificial intelligence-based software for checking real-world echocardiography can improve the early and accurate detection of hidden cardiac amyloidosis.Findings showed that this AI software identified around 5%… View more
Job title: Director of Cardiac Services
Job title: Head (Department of Cardiac Rehabilitation)